Understanding Hemophilia A
Hemophilia A is an inherited bleeding disorder caused by a deficiency of clotting Factor VIII, leading to prolonged bleeding after injury, surgery, or spontaneously into joints and muscles.
- X-linked inheritance
- Factor VIII deficiency
- Lifelong management
- Most Common In
- Males (X-linked recessive)
- Estimated Prevalence
- ~1 in 5,000 male births
- Deficient Factor
- Factor VIII
- Advanced Therapies
- Gene therapy, non-factor agents
Condition Overview
Hemophilia A is the most common severe inherited bleeding disorder, resulting from mutations in the F8 gene that reduce or eliminate production of clotting Factor VIII. Without enough Factor VIII, blood cannot clot normally, leading to prolonged or excessive bleeding after injuries, dental work, or surgery, and in severe cases, spontaneous bleeding into joints and muscles.
Types and Classification
Hemophilia A is classified by the amount of functional Factor VIII present in the blood, which correlates with bleeding severity.
Symptoms and Signs
Symptoms vary with severity but typically center around abnormal bleeding and its consequences.
Causes and Risk Factors
Hemophilia A is most often inherited, though a smaller proportion of cases arise spontaneously or develop later in life.
Diagnosis and Investigations
Diagnosis combines clinical history, bleeding assessment, and specific laboratory coagulation testing.
Severity Classification
Hemophilia A severity is staged by residual Factor VIII activity, which guides expected bleeding pattern and treatment intensity.
Standard Treatment
Treatment centers on replacing or supporting the deficient Factor VIII to prevent and control bleeding episodes.
Advanced & Emerging Therapies
Newer non-factor therapies and gene therapy are expanding treatment options beyond traditional factor replacement.
Gene Therapy
AAV-based Factor VIII gene therapy
Aims to provide sustained endogenous Factor VIII production after a single infusion; approved in select regions for eligible adults.
Non-Factor Replacement
Bispecific antibody (factor-mimetic) therapy
Mimics the function of activated Factor VIII to promote clotting, including in patients with inhibitors.
Extended Half-Life Factor Concentrates
Modified Factor VIII products
Reduce infusion frequency by extending the half-life of replacement factor.
Rebalancing Agents
Anti-TFPI and antithrombin-lowering therapies
Investigational approaches that rebalance coagulation independent of Factor VIII levels.
Biomarkers & Monitoring
Laboratory markers guide diagnosis, severity classification, and treatment monitoring.
When to Seek a Second Opinion
A second opinion can help confirm diagnosis, optimize prophylaxis, or address treatment-resistant bleeding.
Clinical Trials & Research
Prognosis & Outcomes
With appropriate treatment, most people with Hemophilia A lead active lives, though long-term joint health depends on early and consistent bleed prevention.
Supportive Care
Comprehensive supportive care helps reduce bleeding complications and preserve quality of life.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with Hemophilia A access specialist hematology review, evaluate eligibility for gene therapy or newer non-factor agents, and coordinate care with leading treatment centers.
Get a free case reviewFrequently Asked Questions
Hemophilia A is an inherited bleeding disorder caused by a deficiency of clotting Factor VIII, leading to prolonged or excessive bleeding.
It primarily affects males due to X-linked inheritance, though female carriers can sometimes have mild symptoms.
There is no widely available cure, but gene therapy in select regions may provide long-term Factor VIII production for eligible patients.
Diagnosis involves clotting tests such as aPTT along with a Factor VIII activity assay to confirm and grade severity.
Bleeds can occur after injury, surgery, or dental work, and in severe cases, spontaneously into joints or muscles.
An inhibitor is an antibody that neutralizes replacement Factor VIII, making standard treatment less effective.
Yes, women can be carriers and pass the gene to their children, and some carriers experience mild bleeding symptoms themselves.
Gene therapy delivers a functional copy of the F8 gene to help the body produce its own Factor VIII, reducing or eliminating the need for regular infusions.
Prophylaxis involves regular scheduled infusions to prevent bleeds, while on-demand treatment is given only when a bleed occurs.
Yes. CancerFax assists with medical report review, second opinion coordination, and access to advanced therapies including gene therapy, with support for international treatment coordination where relevant.
Get Expert Guidance on Hemophilia A
Send your medical reports for a specialist review and explore the latest treatment and therapy options available to you.